Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer

Chieh Chien Lee, Hui Yi Shiao, Wen Chieh Wang, Hsing Pang Hsieh

Research output: Contribution to journalReview articlepeer-review

40 Citations (Scopus)


Introduction: EGFR has been implicated in various malignancies such as NSCLC, breast, head and neck, and pancreatic cancer. Numerous drugs have been developed in order to target the tyrosine domain of EGFR as an approach in cancer treatment.Areas covered: This article focuses on the different generations of EGFR tyrosine kinase inhibitors (TKIs). This spans from the emergence of the first-generation EGFR-TKIs to overcoming drug resistance using second-generation EGFR-TKIs and to reducing adverse effect (AE) using mutant-selective third-generation EGFR-TKIs.Expert opinion: Current TKI treatment is frequently accompanied by drug resistance and/or serious AEs. There has been the promise of advancements in second-generation EGFR-TKIs that could overcome drug resistance, acting as second- or third-line salvage treatment, but this promise has yet to be met. That being said, both issues are currently being addressed with mutant-selective EGFR-TKIs with the expectation of bringing more EGFR-targeted therapy into the next phase of cancer therapy in the future.

Original languageEnglish
Pages (from-to)1333-1348
Number of pages16
JournalExpert Opinion on Investigational Drugs
Issue number10
Publication statusPublished - 2014 Oct 1

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer'. Together they form a unique fingerprint.

Cite this